Home ›
Entities
› academia
› Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective
Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective
Research article (Cost Effectiveness and Resource Allocation, 2018) · cited 13× · AI/ML
Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective
Summary
Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective is a scholarly article[1].
Key Facts
Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective's instance of is recorded as scholarly article[2].
References
Programmatic citations — every numbered marker resolves to a verifiable graph row below.
Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.
APA4ort.xyz Knowledge Graph. (2026). Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective. Retrieved May 24, 2026, from https://4ort.xyz/entity/cost-effectiveness-analysis-of-secukinumab-versus-other-biologics-and-apremilast-in-the-treatment-of-active-psoriatic-ar
MLA“Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective.” 4ort.xyz Knowledge Graph, 4ort.xyz, 24 May. 2026, https://4ort.xyz/entity/cost-effectiveness-analysis-of-secukinumab-versus-other-biologics-and-apremilast-in-the-treatment-of-active-psoriatic-ar.
BibTeX@misc{4ortxyz_cost-effectiveness-analysis-of-secukinumab-versus-other-biologics-and-apremilast-in-the-treatment-of-active-psoriatic-ar_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective}}, year = {2026}, url = {https://4ort.xyz/entity/cost-effectiveness-analysis-of-secukinumab-versus-other-biologics-and-apremilast-in-the-treatment-of-active-psoriatic-ar}, note = {Accessed: 2026-05-24}}
LLM promptAccording to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective — https://4ort.xyz/entity/cost-effectiveness-analysis-of-secukinumab-versus-other-biologics-and-apremilast-in-the-treatment-of-active-psoriatic-ar (retrieved 2026-05-24)
